Amanda H. Mdlophane

Pretoria, GT, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Targeted alpha therapy in prostate cancer: review of available agents in clinical practice.

Targeted alpha therapy in prostate cancer: review of available agents in clinical practice.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: July 03, 2025

An Insight to Nanoliposomes as Smart Radiopharmaceutical Delivery Tools for Imaging Atherosclerotic Plaques: Positron Emission Tomography Applications.

An Insight to Nanoliposomes as Smart Radiopharmaceutical Delivery Tools for Imaging Atherosclerotic Plaques: Positron Emission Tomography Applications.

Journal: Pharmaceutics

Published: December 14, 2024

IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals.

IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals.

Journal: Nuclear medicine and biology

Published: November 14, 2024

Evaluation of [68Ga]Ga-DOTA-AeK as a Potential Imaging Tool for PET Imaging of Cell Wall Synthesis in Bacterial Infections.

Evaluation of [68Ga]Ga-DOTA-AeK as a Potential Imaging Tool for PET Imaging of Cell Wall Synthesis in Bacterial Infections.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 05, 2024

Insights into Peptidoglycan-Targeting Radiotracers for Imaging Bacterial Infections: Updates, Challenges, and Future Perspectives.

Insights into Peptidoglycan-Targeting Radiotracers for Imaging Bacterial Infections: Updates, Challenges, and Future Perspectives.

Journal: ACS infectious diseases

Published: January 30, 2024

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium.

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium.

Journal: Frontiers in nuclear medicine

Published: December 14, 2023

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.

Journal: The Lancet. Oncology

Published: October 26, 2023

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.

Journal: Pharmaceutics

Published: April 17, 2023

Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.

Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 09, 2022

mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.

mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 30, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026